The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The reason,and the only reason I am invested in Sar is the shares I hold are in paper certificated form(have you tried dealing with. paper share certicates...not straightforward...call me lazy......proof positive how long I have been invested here also).10 years down the line we should have at least one of our compounds in pase 3 trials.It's just a constant round of conferences/poster presentations(a jolly/**** up for the boys...I know...been there loads of times).Where's the real news?????.If we had anything the big pharma's would be all over us.End of my yearly visit to this bb.Currently in novacyt(got in at 23p,smug as fcuk)Genuinely GLA.
I sold most of my Val at a loss ages ago , they have less commercial acumen than sar, although sar could easily go the same way
Agreed Ahfam
All we need now are the likes of Mr O to raise from the ashes and the game is on.
JonT always said the c..wombles would turn up when something was afoot both rampers and derampers. Maybe the time is nigh.
I too have been on this dogs back for a similar amount of time( in at 1.2 p.I remember it hitting 4p once.
If this ever gets off the ground I may make something,but if I have to wait another 10 years I probably wont see the benefit.
Fair pplay to the Val shareholders getting mobilised and following through. should send some shudders through several other boards on aim. Im quite happy with sar atm, but the val bod have been taking the **** for years
cfh- maybe you should cut your losses and move to Val-
https://www.ii.co.uk/news/valirxs-future-in-doubt-as-investors-say-no-to-capital-reogranisation-al1581943708431570100
then they did the same with Alderley Park after investing 100's of millions on the site.......
When I worked there,Fison s was taken over by Rhone Poulenc(trademark grab....not interested with the reaearch side of things).The pharmaceutical R&D side of things was relatively quickly sold to the swedish giant Astra,who bought Zeneca from ICI.....Astra Zeneca.Invested in a 30million pounds(complete guess..not far off) complex around 1994/5.Closed down a few years ago.Tragic.
ah ok - I guess you worked at Astra site Charnwood then before it shut down.
I am referring to Fisons.
Pharmaceutical side(Loughborough...chee ky so and so).Lol.
Hi cfhmetal - I agree its frustrating at times, especially the drop over the last 18 months.
Surely something must have attracted you to begin with.
Did you work on the pharmaceutical or agrochemical sides of those companies?
I am hopeful that this is our year for Sareum, hopefully the "significant shareholder value" statement comes true in 2020.
When you come back from holidays I would sell SAR and put more into your winners at NYCT and GGP, surely you shouldn’t stick with it any longer especially if it upsets you, what people do on chat site is chat on possibilities and try and research with input so I think a few of us are happy to do that, but understand if your been invested 10years a return on that investment you would think should have happened in the timeframe!
Sorry to **** on anyone 's campfire.Been invested(what a joke) in this ongioing disaster for at least 10yrs.I'm on holiday so I can't acsess my investment records,but my guess is not far off.Ex research chemist in Pharmaceutical design and synthesis,who has worked for Fisons,Rhone Poulenc,Knoll(BASF),Astra,Astra Zeneca.If th is shower of a company had anything it would be well on it's way to commercial development.Instead the compounds they have(many of which appear to have fallen by the wayside),are being pushed from pillar to post to generate headlines,to support the sp and the board's salary.Now we have Coronavirus,sepsis,etc. etc. beingi chucked around.Talk about flogging a dead horse.Wake up folks.
d anything
You would have thought that inhibiting JAK1 is necessary for this indication a dual inhibitor for the other Interleukins other than IL-12/IL-23 which a selective TYK2 would just inhibit, where a JAK1 would inhibit other Interleukins IFN-a, IL-6, IL-10, and IL-22 so a TYK2/JAK1 would maybe suit Sareum’s molecule SDC-1801 better!
It would be make business sense to go for an indication that BMS/Nimbus haven’t got a selective TYK2 in the clinic, like the novel SDC-1802 in B-Cell Acute Lymphoblastic Leukaemia and Solid Tumors!
if tyk2 mediates cytokine storm that leads to sepsis, could be used as breakthrough treatment for coronavirus
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30305-6/fulltext
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378830/
But might be putting 2 and 2 together to get 5...
I don't recall who previously mentioned sepsis as a possible target however interesting to note the 2013 reference by SRI to sepsis and wondering whether the selection of of most efficacious/lucrative target is the reason for the ongoing delays in publication of the SRI DoD paper?
http://www.sareum.com/news/press-releases-and-news/2013/sareum-and-sri-international-announce-co-development-agreement/
Because of TYK2’s critical role in the signalling of inflammatory cytokines, there is strong scientific rationale for developing TYK2 inhibitors for the treatment of autoimmune and inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, sepsis, and Crohn’s Disease,” said Annalisa D’Andrea, Ph.D., senior director of SRI’s Center for Immunology and Infectious Diseases. “Combining SRI’s expertise in autoimmune and inflammatory diseases with Sareum’s experience in compound design will enable us to develop much-needed products that may benefit people throughout the world.”
D'Andrea currently CSO at Kiniksa - KNSA